Citations

Clear

63 citation(s) found for "Smith, Steven".

Improvement in chronic pelvic pain, orthostatic intolerance and interstitial cystitis symptoms after treatment of pelvic vein insufficiency
Smith, Steven J. , Sichlau, Michael J. , Chen, Brenda, Rowe, Peter C. , Smith, B Holly , Knight, Dacre Rt, Rowe, Peter C , Knight, Dacre R T

Mayo Clinic

Phlebology: The Journal of Venous Disease | December 5, 2023 | Volume: 39 | Issue: 3 | Pages: 202-213

10.1177/02683555231219737 | PMID 38050791 Get It

Objectives Comorbidities associated with venous origin chronic pelvic pain (VO-CPP) were evaluated pre and post venous treatment to assess change. Materials and methods 45 women with VO-CPP were treated with venous stenting and/or embolization. Four surveys assessed symptoms pre- and post-treatment: IPPS (chronic pelvic pain), PUF (interstitial cystitis), OHQ (dysautonomia), and modified ROME III (IBS). Prevalence of joint hypermobility was investigated. Results Ages were 18–65. Pretreatment, 64% and 49% of women were in the severe range for PUF and OHQ, respectively. 40% and 56% met criteria for IBS and Ehlers-Danlos syndrome/Hypermobility Spectrum Disorder (EDS/HSD), respectively. 17eceived an iliac stent, 5 pelvic embolization, and 23 both. Post-treatment, average scores improved: IPPS (by 55%), PUF (34%), and OHQ (49%). Rome III improved only slightly. Conclusion Pelvic pain, interstitial cystitis, and dysautonomia were frequently found with VO-CPP and improved after venous treatment. EDS/HSD and IBS were common in these women.
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase
Krysiak, Kilannin , Danos, Arpad , McMichael, Joshua F. , Coffman, Adam , Kiwala, Susanna , Sheta, Lana , Kujan, Lynzey , Pema, Shahil , Ridd, Sarah , Spies, Nicholas C. , Andric, Veronica , Chiorean, Andreea , Rieke, Damian , Clark, Kaitlin A., Reisle, Caralyn , Venigalla, Ajay C, Jani, Payal , Takahashi, Hideaki , Suda, Avila, Horak, Peter , Ritter, Deborah , DeLong, Sean , Lamping, Mario , Shen, Haolin , Marr, Alexander , Hoang, My , Singhal, Kartik , Khanfar, Mariam , Li, Brian V , Lin, Wan‐Hsin , Terraf, Panieh, Corson, Laura , Salama, Yasser, Farncombe, Kirsten M. , Ji, Jianling , Zhao, Xiaonan, Xu, Xinjie , Kanagal‐Shamanna, Rashmi , Walker, Jason , Zhang, Jinghui , Patel, Ronak Y. , Kim, Raymond H. , Jones, Steven J.M. , Raca, Gordana , Madhavan, Subha , Griffith, Malachi , Griffith, Obi L. , Coffman, Adam C , Kiwala, Susanna , Zhou, Xin , Campbell, Katie M , Ji, Jianling , Cotto, Kelsy C , Schriml, Lynn M , Wagner, Alex H , Griffith, Malachi , Griffith, Obi L , Krysiak, Kilannin , Kanagal-Shamanna, Rashmi , Kim, Raymond H , Saliba, Jason , Barnell, Erica K. , Grisdale, Cameron J. , Lever, Jake , Venigalla, Ajay , Evans, Mark G. , Ainscough, Benjamin J. , Kesserwan, Chimene A. , Zhao, Xiaonan, King, Ian F. G. , Skidmore, Zachary L. , Milosavljevic, Aleksandar , Giles, Rachel H. , Mardis, Elaine R. , Rao, Shruti , Wagner, Alex H. , Khanfar, Mariam

Mayo Clinic

Nucleic Acids Research | October 15, 2022 | Volume: 51 | Issue: D1 | Pages: D1230-D1241

10.1093/nar/gkac979 | PMID 36373660 Get It

Abstract CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence Items) that can be accessed globally and in real time, reducing barriers to clinical variant knowledge sharing. We have extended CIViC’s functionality to support emergent variant interpretation guidelines, increase interoperability with other variant resources, and promote widespread dissemination of structured curated data. To support the full breadth of variant interpretation from basic to translational, including integration of somatic and germline variant knowledge and inference of drug response, we have enabled curation of three new Evidence Types (Predisposing, Oncogenic and Functional). The growing CIViC knowledgebase has over 300 contributors and distributes clinically-relevant cancer variant data currently representing >3200 variants in >470 genes from >3100 publications.
A counseling strategy was better than usual care for adopting and maintaining physical activity in type 2 diabetes
Smith, Steven A., Vickers, Kristin S.

Mayo Clinic

ACP Journal Club | February 17, 2022 | Volume: 139 | Issue: 3 | Pages: 69

10.7326/acpjc-2003-139-3-069 | PMID 14594420 Get It

Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus
Gami, Apoor S., Smith, Steven A.

Mayo Clinic

ACP Journal Club | February 17, 2022 | Volume: 142 | Issue: 2 | Pages: 29

10.7326/acpjc-2005-142-2-029 | PMID 15739976 Get It

Review: Lifestyle or pharmacologic interventions prevent or delay type 2 diabetes in impaired glucose tolerance
Bhagra, Sumit , Smith, Steven A.

Mayo Clinic

ACP Journal Club | January 18, 2022 | Volume: 147 | Issue: 1 | Pages: 1

10.7326/acpjc-2007-147-1-001 | PMID 17608366 Get It

Review: Long-acting insulin analogues do not improve glycemic control but do reduce nocturnal hypoglycemia in diabetes
Smith, Steven A., Murad, M. Hassan

Mayo Clinic

ACP Journal Club | October 28, 2021 | Volume: 148 | Issue: 2 | Pages: 37

10.7326/acpjc-2008-148-2-037 | PMID 18311867 Get It

Review: Tricyclic antidepressants, anticonvulsants, opioids, and capsaicin cream are effective treatments for diabetic neuropathy
Smith, Steven A., Murad, M. Hassan

Mayo Clinic

ACP Journal Club | October 28, 2021 | Volume: 148 | Issue: 1 | Pages: 2

10.7326/acpjc-2008-148-1-002 | PMID 18170989 Get It

Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey
Akgül, Mahmut , Ertoy, Dilek, Argani, Pedram , Gupta, Sounak , Reuter, Victor E. , Tickoo, Satish K. , Netto, George J. , Hes, Ondřej , Hirsch, Michelle S. , Delahunt, Brett , Mehra, Rohit , Skala, Stephanie L. , Osunkoya, Adeboye O. , Harik, Lara R. , Nourieh, Maya , Zynger, Debra L. , Smith, Steven Cristopher, Nazeer, Tipu, Kulaç, İbrahim , Khani, Francesca , Tretiakova, Maria , Vakar‐Lopez, Funda , Barkan, Güliz A. , Molinié, Vincent , Verkarre, Virginie , Rao, Qiu , Kis, Lóránd, Panizo, Ángel , Farzaneh, Ted , Magers, Martin J. , Sanfrancesco, Joseph, Perrino, Carmen M. , Gondim, Dibson , Araneta, Ronald, So, Jeffrey , Ro, Jae Y. , Wasco, Matthew J., Hameed, Omar , Wobker, Sara E. , Melamed, Jonathan , Cheng, Liang , Idrees, Muhammad T. , Gumuskaya, Berrak , Samaratunga, Hemamali , Cheng, Liang , Skala, Stephanie L , Tretiakova, Maria S , Williamson, Sean R. , Caliò, Anna , Al-Ahmadie, Hikmat A , Rao, Priya , Sangoi, Ankur R. , López-Beltrán, Antonio , Samaratunga, Hemamali

Mayo Clinic

Journal of Clinical Pathology | January 29, 2021 | Volume: 74 | Issue: 5 | Pages: 291-299

10.1136/jclinpath-2020-207372 | PMID 33514585 Get It

Transcription factor E3-rearranged renal cell carcinoma (TFE3-RCC) has heterogenous morphologic and immunohistochemical (IHC) features. 131 pathologists with genitourinary expertise were invited in an online survey containing 23 questions assessing their experience on TFE3-RCC diagnostic work-up. Fifty (38%) participants completed the survey. 46 of 50 participants reported multiple patterns, most commonly papillary pattern (almost always 9/46, 19.5%; frequently 29/46, 63%). Large epithelioid cells with abundant cytoplasm were the most encountered cytologic feature, with either clear (almost always 10/50, 20%; frequently 34/50, 68%) or eosinophilic (almost always 4/49, 8%; frequently 28/49, 57%) cytology. Strong (3+) or diffuse (>75% of tumour cells) nuclear TFE3 IHC expression was considered diagnostic by 13/46 (28%) and 12/47 (26%) participants, respectively. Main TFE3 IHC issues were the low specificity (16/42, 38%), unreliable staining performance (15/42, 36%) and background staining (12/42, 29%). Most preferred IHC assays other than TFE3, cathepsin K and pancytokeratin were melan A (44/50, 88%), HMB45 (43/50, 86%), carbonic anhydrase IX (41/50, 82%) and CK7 (32/50, 64%). Cut-off for positive TFE3 fluorescent in situ hybridisation (FISH) was preferably 10% (9/50, 18%), although significant variation in cut-off values was present. 23/48 (48%) participants required TFE3 FISH testing to confirm TFE3-RCC regardless of the histomorphologic and IHC assessment. 28/50 (56%) participants would request additional molecular studies other than FISH assay in selected cases, whereas 3/50 participants use additional molecular cases in all cases when TFE3-RCC is in the differential. Optimal diagnostic approach on TFE3-RCC is impacted by IHC and/or FISH assay preferences as well as their conflicting interpretation methods.
Imaging findings of pelvic venous insufficiency in patients with postural orthostatic tachycardia syndrome
Knuttinen, Martha-Gracia, Zurcher, Kenneth S. , Khurana, Neal , Patel, Indravadan , Foxx–Orenstein, Amy E., Harris, Lucinda A. , Lawrence, Andrew, Aguilar, Francisco , Sichlau, Michael J. , Smith, Steven J. , Foxx-Orenstein, Amy, Zurcher, Kenneth , Lawrence, Andrew, Smith, B Holly

Mayo Clinic

Phlebology: The Journal of Venous Disease | August 6, 2020 | Volume: 36 | Issue: 1 | Pages: 32-37

10.1177/0268355520947610 | PMID 32757696 Get It

Objectives Some patients with postural orthostatic tachycardia syndrome (POTS) demonstrate improved dysautonomic symptoms following treatment for pelvic venous insufficiency (PVI). This study assessed the prevalence of significant left common iliac vein (LCIV) compression in POTS patients. Methods Radiologists retrospectively reviewed CT images of pelvic veins for 216 women (191 with POTS and 25 age-comparable controls).Quantitative vascular analysis identified percent-diameter compression of the LCIV by the right common iliac artery. Significant LCIV compression was defined as >50%. Results Significant LCIV compression was found in 69% (131/191) of females with POTS versus 40% (10/25) in controls. The hypothesis that venous compression and presence of POTS are independent was rejected ( p = .005). Conclusions Significant LCIV compression was noted in a majority of female POTS patients, suggesting that incidence of iliac venous obstruction may be higher than the general population. Patients with POTS and symptoms of PVI may benefit from assessment for venous outflow obstruction.
Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate
Gandhi, Jatin , Smith, Steven C. , Paner, Gladell P. , McKenney, Jesse K. , Sekhri, Radhika , Osunkoya, Adeboye O. , Baras, Alexander S. , Cheville, John C. , Jiménez, Rafael E. , Trpkov, Kiril , Colecchia, Maurizio , Ro, Jae Y. , Montironi, Rodolfo , Hes, Ondřej , Hirsch, Michelle S. , Netto, George J. , Fine, Samson W. , Sirohi, Deepika , Kaushal, Seema , Robinson, Brian D. , Kweldam, Charlotte F. , Humphrey, Peter A. , Hansel, Donna E. , Schultz, Luciana , Przybycin, Christopher G. , Mehra, Rohit , Kunju, Lakshmi P., Aron, Manju , Kuroda, Naoto , Tavora, Fabio, Grignon, David J. , Epstein, Jonathan I. , Reuter, Victor E. , Amin, Mahul B. , Távora, Fábio , Robinson, Brian D. , Trpkov, Kiril , Marzo, Angelo M. De , Menon, Santosh , Williamson, Sean R. , Sangoi, Ankur R. , Magi‐Galluzzi, Cristina , Shah, Rajal B. , Kryvenko, Oleksandr N. , Kench, James G. , Kwast, Theodorus van der

Mayo Clinic

American Journal of Surgical Pathology | December 24, 2019 | Volume: 44 | Issue: 5 | Pages: 673-680

10.1097/pas.0000000000001417 | PMID 31876580 Get It

Intraductal carcinoma of the prostate (IDC-P) has been recently recognized by the World Health Organization classification of prostatic tumors as a distinct entity, most often occurring concurrently with invasive prostatic adenocarcinoma (PCa). Whether documented admixed with PCa or in its rare pure form, numerous studies associate this entity with clinical aggressiveness. Despite increasing clinical experience and requirement of IDC-P documentation in protocols for synoptic reporting, the specifics of its potential contribution to assessment of grade group (GG) and cancer quantitation of PCa in both needle biopsies (NBx) and radical prostatectomy (RP) specimens remain unclear. Moreover, there are no standard guidelines for incorporating basal cell marker immunohistochemistry (IHC) in the diagnosis of IDC-P, either alone or as part of a cocktail with AMACR/racemase. An online survey containing 26 questions regarding diagnosis, reporting practices, and IHC resource utilization, focusing on IDC-P, was undertaken by 42 genitourinary subspecialists from 9 countries. The degree of agreement or disagreement regarding approaches to individual questions was classified as significant majority (>75%), majority (51% to 75%), minority (26% to 50%) and significant minority (≤25%). IDC-P with or without invasive cancer is considered a contraindication for active surveillance by the significant majority (95%) of respondents, although a majority (66%) also agreed that the clinical significance/behavior of IDC-P on NBx or RP with PCa required further study. The majority do not upgrade PCa based on comedonecrosis seen only in the intraductal component in NBx (62%) or RP (69%) specimens. Similarly, recognizable IDC-P with GG1 PCa was not a factor in upgrading in NBx (78%) or RP (71%) specimens. The majority (60%) of respondents include readily recognizable IDC-P in assessment of linear extent of PCa at NBx. A significant majority (78%) would use IHC to confirm or exclude intraductal carcinoma if other biopsies showed no PCa, while 60% would use it to confirm IDC-P with invasive PCa in NBx if it would change the overall GG assignment. Nearly half (48%, a minority) would use IHC to confirm IDC-P for accurate Gleason pattern 4 quantitation. A majority (57%) report the percentage of IDC-P when present, in RP specimens. When obvious Gleason pattern 4 or 5 PCa is present in RP or NBx, IHC is rarely to almost never used to confirm the presence of IDC-P by the significant majority (88% and 90%, respectively). Most genitourinary pathologists consider IDC-P to be an adverse prognostic feature independent of the PCa grade, although recommendations for standardization are needed to guide reporting of IDC-P vis a vis tumor quantitation and final GG assessment. The use of IHC varies widely and is performed for a multitude of indications, although it is used most frequently in scenarios where confirmation of IDC-P would impact the GG assigned. Further study and best practices recommendations are needed to provide guidance with regards to the most appropriate indications for IHC use in scenarios regarding IDC-P.